Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547863 | 0.84 | CA2 (0.55) | CA2CA1CA12CA4CA6 | |
| SCHEMBL16186188 | 0.82 | CA2 (0.60) | CA2ALDH1A1 | |
| SCHEMBL17315251 | 0.81 | CA2 (0.60) | CA2CA1CA12CA4CA6 | |
| SCHEMBL12380241 | 0.79 | CA2 (0.62) | CA2CA1CA12CA9TSHR | |
| SCHEMBL10060475 | 0.78 | ALDH1A1 (0.40) | CA2CA1CA12CA6CA5A | |
| SCHEMBL19604291 | 0.78 | GRIA4 (0.41) | CA2CA1CA12CA4CA6 | |
| SCHEMBL9908319 | 0.78 | CA2 (0.57) | CA2ALDH1A1 | |
| SCHEMBL1434498 | 0.78 | CA2 (0.64) | CA2CA1CA12CA4CA6 | |
| SCHEMBL23049645 | 0.77 | CYP4F2 (0.55) | CA2CA1CA12CA4CA6 | |
| SCHEMBL11346173 | 0.77 | CA2 (0.69) | CA2CA1CA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-11-29 | — | — | US | disclosed |
| WO-2007114902-A2 | ALKYLTHIOBENZYLPIPERIDINE COMPOUNDS | H.LUNDBECK A/S (DK) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | RORC, RORB, RORA | CA2 3426/4885CA1 4394/4885CA12 4074/4885 |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | RORC, RORB, RORA | CA2 3490/4885CA1 4380/4885CA12 4073/4885 |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | RORB, RORA, RORC | CA2 2873/4885CA1 4045/4885CA12 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.